scholarly journals A Case of Endometrial Stromal Sarcoma with Synchronous Bilateral Adenocarcinoma of Ovary

2012 ◽  
Vol 2012 ◽  
pp. 1-5
Author(s):  
Olga Caramelo ◽  
Carol Marinho ◽  
Teresa Rebelo ◽  
Natália Amaral ◽  
Fernando Mota ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Pelvic Lymphadenectomy ◽  
Endometrioid Adenocarcinoma ◽  
Pelvic Endometriosis ◽  
Uterine Tumor ◽  
Total Hysterectomy ◽  
Stromal Sarcoma ◽  
Adenocarcinoma Of The Ovary ◽  
Pelvic Peritonectomy ◽  
Infracolic Omentectomy

Endometrial stromal tumor is a rare mesenchymal uterine tumor. We report the case of a patient with endometrial stromal sarcoma and concomitant bilateral endometrioid adenocarcinoma of the ovary in the context of pelvic endometriosis. The patient underwent a complete cytoreduction including total hysterectomy and bilateral adnexectomy, pelvic lymphadenectomy, appendicectomy, infracolic omentectomy, and pelvic peritonectomy. This is the first report to our knowledge that describes a synchronous endometrial stromal sarcoma and bilateral endometrioid adenocarcinoma of the ovary.

Uterine sarcomas: Analysis of clinicopathologic factors and treatment outcomes—A single institution experience in long-term disease control.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15522-e15522
Author(s):  
Mylene Sy Go ◽  
Le Wang ◽  
Michael Styler ◽  
Stephanie King
Keyword(s):  
Radiation Therapy ◽  
Survival Analysis ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Survival Benefit ◽  
Endometrial Stromal Sarcoma ◽  
Pelvic Lymphadenectomy ◽  
External Beam Radiation ◽  
Uterine Sarcomas ◽  
Stromal Sarcoma

e15522 Background: Uterine sarcomas behave aggressively and are associated with poor prognosis. Carcinosarcomas was re-classified as more akin to endometrial adenocarcinomas. The objective was to analyze the survival outcomes of all uterine sarcomas treated with various combinations of chemotherapy, radiation, and lymph node dissections. Methods: 60 patients with proven uterine sarcomas were treated at Hahnemann Hospital from 2002-2011. Survival analyses in each treatment group were performed by Kaplan- Meier method Results: Among the 60 women examined, 51% were carcinosarcoma, 25% leiomyosarcoma, 20% endometrial stromal sarcoma, and 4% adenosarcoma. 27% presented with stage I disease, 20% stage II, 13% stage III, and 40% with metastatic disease at diagnosis. One third of the leiomyosarcomas and endometrial stromal sarcomas have advanced disease at diagnosis. Median survival of all patients was 26 months, 20 months for carcinosarcoma, 25 months for high grade endometrial stromal sarcoma, and a trend toward superior overall survival at 73 months for leiomyosarcoma. After surgery, 51% of patients mostly carcinosarcomas received carboplatin and paclitaxel as adjuvant chemotherapy and 66% of leiomyosarcomas received gemcitabine and docetaxel. However, the survival analysis showed no statistically significant benefit in disease progression free survival. On the other hand, 50% of patients were also treated with adjunctive pelvic external beam radiation and 21% received additional vaginal brachytherapy. Our results demonstrated a small but clear survival benefit after pelvic radiation therapy. Pelvic lymphadenectomy was performed in 55% of these patients and lymph node involvement was found in 30% of uterine sarcomas mostly carcinosarcomas. Survival analysis indicated that pelvic lymphadenectomy was associated with significant survival benefit. Conclusions: Size, stage, nodal involvement, and histology are independent prognostic factors. Complete cytoreduction followed by lymph node dissection, and radiation therapy offered a survival advantage than surgery alone. However, the role of adjuvant chemotherapy remains uncertain.

scholarly journals Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor

2015 ◽  
Vol 13 ◽  
pp. 8-12 ◽  
Author(s):  
Grace Kim ◽  
Huyen Q. Pham ◽  
Amin Ramzan ◽  
Esther Elishaev ◽  
Paulette Mhawech-Fauceglia
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Collision Tumor ◽  
Endometrioid Adenocarcinoma ◽  
Stromal Sarcoma

scholarly journals Collision tumor of endometrial stromal sarcoma and squamous cell cancer: A rare entity

2016 ◽  
Author(s):  
Bindiya Gupta ◽  
Shalini Rajaram ◽  
Sandhya Jain ◽  
Neerja Goel ◽  
Naveen Tanwar
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Cancer ◽  
Uterine Cavity ◽  
Endometrial Stromal Sarcoma ◽  
Collision Tumor ◽  
Pelvic Lymphadenectomy ◽  
Stromal Sarcoma ◽  
Immunohistochemical Studies

A collision tumor is defined by the presence of two separate tumors in one organ on gross, microscopic, and immunohistochemical studies and they should be distinguished from malignant mullerian mixed tumors. A 60 year old lady P8L8 presented with blood stained vaginal discharge and post menopausal bleeding. Examination revealed a 1 x 2 cm cervical growth which was reported as squamous cell carcinoma cervix. Imaging revealed myohyperplasia with normal uterine cavity. The patient underwent Type III radical hysterectomy, bilateral salphingo-oophorectomy and bilateral pelvic lymphadenectomy. The uterine corpus revealed 5 cm growth in uterine cavity which was reported as high grade endometrial stromal sarcoma and the cervical growth was non keratinising squamous cell carcinoma infiltrating the former. The lymph nodes, parametria and vaginal cuff were free of tumor. The patient was referred for adjuvant chemotherapy and radiation therapy.

Cytoreduction as a remedial procedure improves disease-free survival of patients with occult uterine sarcoma undergoing morcellation——a retrospective study

2020 ◽  
Author(s):  
Chao Ding ◽  
Jianqing Zhu
Keyword(s):  
Disease Free Survival ◽  
Endometrial Stromal Sarcoma ◽  
Uterine Sarcoma ◽  
Uterine Leiomyosarcoma ◽  
Uterine Sarcomas ◽  
Free Survival ◽  
Total Hysterectomy ◽  
Stromal Sarcoma ◽  
Significant Difference ◽  
Disease Free

Abstract Background：Tumor morcellation happened to facilitate iatrogenic metastasis for patients with occult uterine sarcoma. The optimal remedial procedure for these patients needed to be established. Methods：Data were retrospectively collected and analyzed from patients with occult uterine sarcoma undergoing morcellation. Results：23 consecutive patients with uterine sarcomas undergoing morcellation were accessed between Jan 2008 and Dec 2018, including 15 patients with uterine leiomyosarcoma and 8 with endometrial stromal sarcoma. Cytoreduction as a remedial procedure was significantly associated with better disease-free survival (P=0.031), and none of 7 patients undergoing cytoreduction suffered recurrence, while total hysterectomy (P=0.194) and adjuvant therapy (P=0.159) had no such benefit. There was no significant difference in disease-free survival between laparoscopic and open surgery (p=0.321). Conclusion：Cytoreduction was considered as the optimal remedial procedure for patients with occult uterine sarcoma undergoing morcellation.

scholarly journals High grade endometrial stromal sarcoma: a clinician dilemma

2021 ◽  
Vol 9 (8) ◽  
pp. 2493
Author(s):  
Poojan Dogra ◽  
Shuchi Sharma ◽  
Reena Sharma ◽  
Suraj Bhardwaj
Keyword(s):  
Tumor Cells ◽  
Pelvic Mass ◽  
Endometrial Stromal Sarcoma ◽  
Exploratory Laparotomy ◽  
Total Abdominal Hysterectomy ◽  
Abdominal Hysterectomy ◽  
Anterior Wall ◽  
Pelvic Lymphadenectomy ◽  
Stromal Sarcoma ◽  
Endometrial Thickening

Uterine sarcomas are relatively rare tumors of mesodermal origin. ESS occurs primarily in perimenopausal women in 4th and 5th decade of their life; about one third occurs in postmenopausal women. Here in we describe a case of 44 years old patient presented with one month history of foul smelling discharge per vagina and a pelvic mass. Ultrasound and MRI gave possibility of a large anterior wall and fundal fibroid with degeneration versus neoplastic endometrial thickening. The patient underwent exploratory laparotomy with total abdominal hysterectomy with bilateral salpingoophorectomy with pelvic lymphadenectomy. Histopathology showed tumor cells with round to oval nuclei with high mitotic activity, blood vessel proliferation between the tumor cells and extensive lymphovascular invasion. The pathological diagnosis was HG-ESS stage IB. The patient was referred to radiotherapy department for adjuvant therapy. HG-ESS is a rare clinical entity and considered as important differential diagnosis.

Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5595-5595
Author(s):  
T. W. Burke ◽  
M. A. Navo ◽  
J. A. Smith ◽  
M. S. Jung ◽  
R. Broaddus ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adverse Events ◽  
Phase Ii ◽  
Stable Disease ◽  
Single Agent ◽  
Female Genital Tract ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Endometrioid Adenocarcinoma ◽  
Stromal Sarcoma

5595 Background: Endometrial cancer is the most common cancer of the female genital tract. It affected 41,200 women in the year 2006 and caused 7,350 deaths. Therapy options for recurrent/advanced endometrial cancer are limited. Treatment with radiation and chemotherapy has shown only limited success. Methods: In a phase II IRB approved trial, Mifepristone was given to patients with progesterone receptor positive advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma at a dose of 200mg/day orally. Patients were evaluated every 4 weeks to assess treatment-related toxicities and response. Imaging was obtained initially at 8 weeks then every 12 weeks for evaluation of response. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to assess toxicity. Results: Twelve of 13 enrolled patients were evaluable for response in the first phase of accrual. Stable disease was noted in 3/12 (16, 20, and 44+ weeks). Two were endometrioid endometrial cancer and one with LGESS. No complete responses were seen, one patient remains in treatment. The most frequently reported grade 1–2 tumor related toxicities were anorexia, mood alterations, and fatigue (55%). Twenty-seven percent had asymptomatic elevations of ACTH. The most common Grade 3 toxicities were fatigue and dyspnea (27% and 18%). Only one patient experienced a Grade 4 dyspnea. No serious treatment-related adverse events occurred. Conclusions: Single agent mifepristone in patients with recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma showed no complete responses. Stable disease was reported 25%, one patient remains stable at 44 weeks. Recent reports suggests that mifepristone may also work via non hormonal targets while single agent mifepristone has minimal activity in this setting. Further evaluation in combination therapy in endometrial cancer should be considered. No significant financial relationships to disclose.

scholarly journals Endometrial stromal sarcoma occurring 20 years after total hysterectomy for myomas

2014 ◽  
Vol 3 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Yen-Feng Lu ◽  
Ben-Shian Huang ◽  
Chiung-Ru Lai ◽  
Kuan-Chin Wang ◽  
Ming-Shyen Yen ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Total Hysterectomy ◽  
Stromal Sarcoma

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

Cancer ◽  
2009 ◽  
Vol 115 (9) ◽  
pp. 1867-1874 ◽  
Author(s):  
Lois M. Ramondetta ◽  
Alaina J. Johnson ◽  
Charlotte C. Sun ◽  
Neely Atkinson ◽  
Judith A. Smith ◽  
...  
Keyword(s):  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Endometrioid Adenocarcinoma ◽  
Phase 2 ◽  
Ru 486 ◽  
Phase 2 Trial ◽  
Stromal Sarcoma
Sign in / Sign up

Export Citation Format

Share Document